Stock Price Quote

SYNCOM FORMULATIONS (INDIA) LTD.

NSE : SYNCOMFBSE : 524470ISIN CODE : INE312C01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE14.040.17 (+1.23 %)
PREV CLOSE ( ) 13.87
OPEN PRICE ( ) 14.19
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1354982
TODAY'S LOW / HIGH ( )13.95 14.45
52 WK LOW / HIGH ( )5.9 18.65
NSE14.050.25 (+1.81 %)
PREV CLOSE( ) 13.80
OPEN PRICE ( ) 14.10
BID PRICE (QTY) 14.05 (14301)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3829395
TODAY'S LOW / HIGH( ) 14.00 14.45
52 WK LOW / HIGH ( )5.9 18.65
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1988
Management Info
Kedarmal Bankda - Chairman Vijay Shankarlal Bankda - Managing Director
Registered Office

Address 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E),
Mumbai,
Maharashtra-400093

Phone 022 26877711

Email finance@sfil.in

Website www.sfil.in

Registrars Details
Ankit Consultancy Pvt Ltd
Plot No 60,Electronic Complex,Pardeshipura,Indore
Listing : BSE, NSE

NEWS

05Apr Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that it enclosed Certificate fo..
26Feb Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that both the Stock Exchanges,..
29Aug Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that the 35th Annual General Me..
13Jan Syncom Formulations (India) submits re
With reference to the compliance of Regulation 76 of SEBI (Depositories..
20Sep Syncom Formulations (India) informs ab
Pursuant to the Regulation 30(2) read with Part A of Schedule III of the..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit64.21200.7
Gross Profit 85.97 265.66
Operating Profit 111.49342.22
Net Sales 633.422246.44

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2621.00 (5.75%)
M.Cap ( in Cr)1619.26
Glaxosmithkline Phar (BSE)
peergroup  2079.80 (7.06%)
M.Cap ( in Cr)35233.07
TTK Healthcare (BSE)
peergroup  1591.35 (5.77%)
M.Cap ( in Cr)2248.63
Cipla (BSE)
peergroup  1398.80 (3.79%)
M.Cap ( in Cr)112938.41
Torrent Pharma (BSE)
peergroup  2685.00 (1.85%)
M.Cap ( in Cr)90872.60

Shareholding Pattern

PROMOTERS 50.57%
NON-INSTITUTION 49.35%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Syncom Formulations (India) Ltd.

Syncom Formulations (India) Ltd. was incorporated in the year 1988. Its today's share price is 14.04. Its current market capitalisation stands at Rs 1319.76 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2246.44 Cr and Total Income of Rs.2392.53 Cr. The company's management includes Vaishali Agrawal, Ankit Jain, Ritesh Kumar Lunkad, Ruchi Jindal, Praveen Jindal, Vinod Kumar Kabra, Krishna Das Neema, Rinki Bankda, Vijay Shankarlal Bankda, Kedarmal Bankda.

It is listed on the BSE with a BSE Code of 524470 , NSE with an NSE Symbol of SYNCOMF and ISIN of INE312C01025. It's Registered office is at 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E)Mumbai-400093, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Sanjay Mehta & Associates, SP Moondra & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.